SKIN CANCERS

Latest News

September 19th 2016

Cancer Stem Cell Therapies on the Horizon for HCC

Technological advances and greater understanding of stem cell biology have contributed to the identification and characterization of the tissues and organs involved with these cells.

September 13th 2016

The Impacts of Chemotherapy Versus Immunotherapy in Melanoma

By Yvonne Saenger, MD

September 12th 2016

Test for colored external link

September 2nd 2016

Weber Speaks on Findings of Immunotherapy Study in Melanoma

By Laura Panjwani

September 2nd 2016

Expert Discusses Immunotherapy Advancements on the Horizon for Melanoma

By Laura Panjwani

Latest Videos

COMBI-AD and BRIM8 Studies in Melanoma

Nivolumab in the Adjuvant Setting for Melanoma

How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care

Impact of CheckMate-238 Results for Patients With Melanoma

Combining an Anti-LAG-3 Antibody With Nivolumab in Melanoma

Avelumab Treatment in Patients With Metastatic Merkel Cell Carcinoma

Dr. Luke Discusses the Combination of Epacadostat and Pembrolizumab in Melanoma

Combining Targeted Therapy With Checkpoint Blockade for the Treatment of Melanoma

Association Between PD-L1/CD8 Expression and Outcomes in Melanoma Patients Who Received Dabrafenib/Trametinib

Activity of Dabrafenib/Trametinib Combo in Patients With Melanoma Brain Metastases

CME Content

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Kamel Abou Hussein, MD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH

Video

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Video

25th Annual International Congress on the Future of Breast Cancer® West

Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD

Video

25th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Virtual Event

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

Webinar Series

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Kurt C. Demel, MD, MBA; Sara A. Hurvitz, MD, FACP

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Kamel Abou Hussein, MD; Yelda Nouri, MD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD

Virtual Event

Tennessee Oncology Practice Society

2 Sessions are Available!

Virtual Event

Kansas Society of Clinical Oncology

2 Sessions are Available!

In-Person + Virtual Event

Satellite Symposia at the Annual Radiation Oncology Meeting

September 27-28, 2026

Virtual Event

North Carolina Oncology Association

2 Sessions are Available!

Virtual Event

Louisiana Oncology Society

2 Sessions are Available!

Video

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

Video

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Tiffany A. Traina, MD, FASCO; Kevin Kalinsky, MD MS, FASCO; Mark E. Robson, MD, FASCO; Rebecca Shatsky, MD

Video

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Video

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Video

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD

Video

Module 4: Breast Surgery (2025)

Eleftherios (Terry) Mamounas, MD, MPH, FACS; Michael Alvarado, MD, MS; Puneet Singh, MD, MS, FACS, FSSO, CMQ

Video

Module 5: Breast Radiation Therapy (2025)

Douglas W. Arthur, MD, FABS, FASTRO; Eleanor E. Harris, MD, FASTRO; Kathleen Horst, MD

Video

Module 3: Pathology And Biomarkers (2025)

Joyce O’Shaughnessy, MD; Sunil S. Badve, MD, FRCPath; Claudine Isaacs, MD; Michael F. Press, MD, PhD

Video

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; N. Lynn Henry, MD, PhD, FASCO; Kevin Kalinsky, MD, MS; Joseph A. Sparano, MD; Sara Tolaney, MD, MPH

Video

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Joyce O’Shaughnessy, MD; Carol Fabian, MD; Rachel Freedman, MD, MPH; Anne Grabenstetter, MD; Claudine Isaacs, MD; Pedram Razavi, MD, PhD

Video

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

William J. Gradishar, MD, FASCO, FACP; Ting Bao, MD, MS; Jennifer A. Ligibel, MD; Filipa Lynce, MD; Ruth O’Regan, MD, MSc

Video

Module 2: Breast Imaging (2025)

Joyce O’Shaughnessy, MD; Connie Lehman, MD, PhD, FACR; David M. Schuster, MD, FACR

Video

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Joyce O’Shaughnessy, MD; Michelle Melisko, MD; Beverly Moy, MD, MPH

Video

Module 9: Toxicity Management And Survivorship Considerations (2025)

Joyce O’Shaughnessy, MD; Laura Huppert, MD; Michelle Melisko, MD; Michelle Mollica, PhD, MPH, RN, OCN; Ann H. Partridge, MD, MPH

More News

Immunotherapy Proves Pivotal in Melanoma, Though the Future Holds Challenges

ByLaura Panjwani

August 24th 2016

Today, the field of melanoma is virtually unrecognizable from what it was not that long ago.

The Role of Immunotherapy and Oncolytic Viruses in the Future of Cancer Treatment

ByGreg Kennelty

August 23rd 2016

Immunotherapy may not phase out surgery and chemotherapy as standards of care in cancer, but oncolytic viruses may usher in a new age of treatment.

SKIN CANCERS

Latest News

Latest Videos

COMBI-AD and BRIM8 Studies in Melanoma

Nivolumab in the Adjuvant Setting for Melanoma

How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care

Impact of CheckMate-238 Results for Patients With Melanoma

Combining an Anti-LAG-3 Antibody With Nivolumab in Melanoma

Avelumab Treatment in Patients With Metastatic Merkel Cell Carcinoma

Dr. Luke Discusses the Combination of Epacadostat and Pembrolizumab in Melanoma

Combining Targeted Therapy With Checkpoint Blockade for the Treatment of Melanoma

Association Between PD-L1/CD8 Expression and Outcomes in Melanoma Patients Who Received Dabrafenib/Trametinib

Activity of Dabrafenib/Trametinib Combo in Patients With Melanoma Brain Metastases

CME Content

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

24th Annual International Congress on the Future of Breast Cancer® East

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

25th Annual International Congress on the Future of Breast Cancer® West

25th Annual International Congress on the Future of Breast Cancer® East

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Tennessee Oncology Practice Society

Kansas Society of Clinical Oncology

Satellite Symposia at the Annual Radiation Oncology Meeting

North Carolina Oncology Association

Louisiana Oncology Society

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

More News

Immunotherapy Proves Pivotal in Melanoma, Though the Future Holds Challenges

The Role of Immunotherapy and Oncolytic Viruses in the Future of Cancer Treatment

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD: Case 2

Jeffrey Weber, MD, PhD: The Association Between Durable Response and Low Disease Burden

Jeffrey Weber, MD, PhD: Predicting Which Patients Will Experience Durable Responses to Targeted Therapy

Jeffrey Weber, MD, PhD: The Role of LDH, Age, and Sites of Disease in Durability of Response

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments

Jason Luke, MD: Predicting Which Patients Will Experience Durable Responses to Targeted Therapy

Jason Luke, MD: The Role of LDH, Age, and Sites of Disease in Durability of Response

Jason Luke, MD: The Association Between Durable Response and Low Disease Burden

Jason Luke, MD: Factors to Consider When Determining Treatments

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD: Case 1

Jason Luke, MD: Second-Line Therapy

Jason Luke, MD: The Impact of BRAF/MEK Inhibitors in Melanoma

Jeffrey Weber, MD, PhD: Second-Line Therapy

Jeffrey Weber, MD, PhD: The Impact of BRAF/MEK Inhibitors in Melanoma

Jason Luke, MD: Durability of a Response to Targeted Therapy Combination

Jeffrey Weber, MD, PhD: Durability of a Response to Targeted Therapy Combination

Jason Luke, MD: The Impact of Moderate Level of Disease Burden on Response to Targeted Therapy

Jeffrey Weber, MD, PhD: The Impact of Moderate Level of Disease Burden on Response to Targeted Therapy

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatment

Jason Luke, MD: Factors to Consider When Determining Treatment

Metastatic Melanoma with Adil Daud, MD and Boris C. Bastian, MD, PhD

Adil Daud, MD: Sequencing Challenges in Melanoma

Adil Daud, MD: Optimal Sequencing for BRAF-Mutant Melanoma

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma

Alert-Based ePRO Monitoring Reduces Fatigue in Metastatic Breast Cancer

AMH Testing Predicts Chemotherapy Benefit in RxPONDER Breast Cancer

ASTRO Issues Updated Clinical Practice Guideline on RT for Pancreatic Cancer

FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma